NIBR’s Marks joins GV as entrepreneur-in-residence
Plus new venture partner and promotions at Arch, and updates from IQVia, Emergence and more
Kevin Marks became entrepreneur-in-residence at GV. Marks, an 11-year veteran of Agios Pharmaceuticals Inc. (NASDAQ:AGIO), joins from Novartis Institutes for BioMedical Research where he was head of oncology drug discovery. General Partner David Schenkein, who co-leads the life science team at GV, chairs Agios’ board.
Arch Venture Partners announced four promotions and the hiring of Olivia Zetter as strategic adviser and venture partner. Ari Nowacek was promoted to partner; Sean Kendall was promoted to partner, Europe; and Corey Ritter and Nilay Thakar were both promoted to principal. Zetter was head of government affairs and AI strategy at National Resilience Inc., which announced a $625 million series D yesterday and was co-founded by Arch’s Robert Nelsen. Nowacek and Kendall both joined Arch in 2015 as analysts...